• How superbugs uses mirror images to crea

    From ScienceDaily@1:317/3 to All on Thu Feb 17 21:30:42 2022
    How superbugs uses mirror images to create antibiotic resistance

    Date:
    February 17, 2022
    Source:
    Duke University
    Summary:
    Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterial
    infection that has become resistant to most of the antibiotics
    used to treat regular staph infections. Computer scientists are
    working to develop new enzyme inhibitors to fight MRSA. In recent
    research, the team discovered how a single small mutation makes
    a big difference in drug efficacy.



    FULL STORY ========================================================================== Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterial
    infection that has become resistant to most of the antibiotics used to
    treat regular staph infections. Duke computer scientist Bruce Donald and collaborators at the University of Connecticut are working to develop
    new enzyme inhibitors to fight MRSA. In research published in PLOS Computational Biology, the team discovered how a single small mutation
    makes a big difference in drug efficacy.


    ==========================================================================
    They examined dihydrofolate reductase (DHFR), an enzyme that
    antibiotics target to fight MRSA. Drugs that inhibit DHFR work a bit
    like locks and keys; they bind to enzymes in MRSA, which have a specific three-dimensional structure that only allows molecules that fit precisely
    to attach to them.

    A mutation can change the structure of a bacterial enzyme and cause drugs
    to lose effectiveness. The F98Y mutation is a well-known resistance
    mutation. A slight change in the 98th amino acid in the DHFR enzyme
    changes a phenylalanine to a tyrosine. "Those two amino acids are
    structurally similar," said Graham Holt, grad student in the Donald lab,
    "but the mutation has a huge effect on the efficacy of the inhibitors." In essence, it changes the lock.

    Pablo Gainza, PhD, former graduate student in the Donald lab, thought
    he should be able to predict this mutation using OSPREY, a suite of
    programs for computational structure-based protein design developed in
    the Donald lab. But he couldn't. After knocking down hypothesis after hypothesis to figure out why he was unable to predict this mutation,
    he went back to examine the starting structure.

    "We looked at the electron density data from the crystallographer
    and found something strange," Donald said. In trying to determine the
    structure of the F98Y mutant, crystallographers used a computer program
    that -- unbeknownst to them -- flipped the chirality, or made a mirror
    image, of the NADPH cofactor to get a better fit. The "flipped" chemical species they discovered through their analysis exists in experimental conditions in the laboratory and plausibly in vivo.

    "Using OSPREY, we discovered this flipped chirality," Donald said,
    "which we believe happened because of the F98Y mutation." As in 2-factor authentication, the single enzyme mutation and the flipped cofactor
    appear to conspire together to evade the inhibitor.

    This "chiral evasion" changes the structural basis for resistance. But now Donald and colleagues know not only how a single small mutation changed
    the lock, but also the structure they need to make a better key --
    a better drug inhibitor.

    "This is the first example of an enzyme that exploits the chirality of
    its cofactor in order to evade its inhibitors," Holt said. "Now that we
    see this happening, that will help inform computational strategies to
    develop better inhibitors." The Donald lab showed that, by taking flipped chirality into account, OSPREY's predictions closely match experimental measurements of inhibitor potency. They worked with collaborators at the University of Connecticut who conducted biochemical experiments to test
    the theory and provide structural evidence.

    "This is only the beginning of the story," Donald said. "Our discovery
    of chiral evasion should lead to more resilient inhibitors: better
    drug designs." Right now, most drug design is reactive, waiting for
    resistance to arise, which it always does. "We hope to make drug design proactive, by using our algorithms to anticipate resistance," Donald said.

    ========================================================================== Story Source: Materials provided by Duke_University. Original written
    by Alissa Kocer. Note: Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Siyu Wang, Stephanie M. Reeve, Graham T. Holt, Adegoke A. Ojewole,
    Marcel
    S. Frenkel, Pablo Gainza, Santosh Keshipeddy, Vance G. Fowler,
    Dennis L.

    Wright, Bruce R. Donald. Chiral evasion and stereospecific
    antifolate resistance in Staphylococcus aureus. PLOS Computational
    Biology, 2022; 18 (2): e1009855 DOI: 10.1371/journal.pcbi.1009855 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/02/220217181730.htm

    --- up 10 weeks, 5 days, 7 hours, 13 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)